XFOR
X4 Pharmaceuticals Inc
NASDAQ · Biotechnology
$3.56
-0.10 (-2.73%)
Open$3.70
Previous Close$3.66
Day High$3.82
Day Low$3.52
52W High$29.80
52W Low$17.02
Volume—
Avg Volume517.4K
Market Cap332.05M
P/E Ratio32.62
EPS$0.71
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+698.3% upside
Current
$3.56
$3.56
Target
$28.42
$28.42
$21.41
$28.42 avg
$38.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 56.15M | 57.05M | 55.03M |
| Net Income | 11.50M | 9.29M | 9.37M |
| Profit Margin | 20.5% | 16.3% | 17.0% |
| EBITDA | 17.32M | 17.50M | 15.80M |
| Free Cash Flow | 7.07M | 7.43M | 8.43M |
| Rev Growth | +18.4% | +3.4% | -0.1% |
| Debt/Equity | 1.03 | 0.94 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |